Specialty Pharma Journal Specialty, Precision & Technology
MADISON, Wis. and NEW YORK, Aug. 22, 2018 /PRNewswire/ — Exact Sciences Corp. (Nasdaq : EXAS ) and Pfizer Inc. (NYSE : PFE ) today announced an agreement through 2021 to co-promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer. Pfizer will join Exact …
Tag Archives: screening
August, 2018
-
10 August
Sarepta Expands its Presence in Gene Therapy through Investment and License Agreement with Lacerta
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that it has made a strategic investment and entered into a license and option agreement with Lacerta Therapeutics, a gene …
-
3 August
Study Finds Lung Cancer Screening Guidelines Inadequate for High-Risk Minorities
Data from a lung cancer screening program at the University of Illinois at Chicago provides evidence that national lung cancer screening guidelines, which were developed based on the National Lung Screening Trial, or NLST, in 2011 and recommend screening based on age and smoking history, may be insufficient for individuals …
May, 2018
-
25 May
Breast Cancer Survivors Aren’t Getting Recommended Number of Mammograms Post-Surgery, Study Finds
FORT WASHINGTON, PA [May 24, 2018] — Breast cancer survivors are not getting the recommended level of screening, post-surgery, according to a newly-published study in JNCCN – Journal of the National Comprehensive Cancer Network. The study was led by Kathryn Ruddy, MD, MPH, Director of Cancer Survivorship for the Department of Oncology, Mayo Clinic …
December, 2017
-
18 December
Early Diagnosis Can Save Babies’ Lives: A Guide to Severe Combined Immunodeficiency Disease (SCID)
A new review provides guidance on a deadly, but rare, disease that is potentially curable if identified early. Severe combined immunodeficiency disease (SCID), known as the “bubble boy disease” in the 1970s, is treatable with a stem cell transplant, gene therapy and other treatments if identified at birth or soon …
-
4 December
Study Evaluates Refractory Epilepsy Screening Tool for Lennox-Gastaut Syndrome
DEERFIELD, Ill.–(BUSINESS WIRE)–Lundbeck today presented data at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C. that demonstrates that the Refractory Epilepsy Screening Tool for LGS (REST-LGS) may help healthcare professionals identify patients who may benefit from further clinical evaluation for Lennox-Gastaut syndrome (LGS). The REST-LGS was developed by …
August, 2017
-
21 August
Comparison of Screening Recommendations Indicates Annual Mammography
When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely discussed recommendations for screening mammography. …
June, 2017
-
7 June
FDA Approves Hologic’s Genius 3D Mammography Exam as the Only Mammogram Superior for Women with Dense Breasts
MARLBOROUGH, Mass., June 7, 2017 /PRNewswire/ — Hologic, Inc. (Nasdaq: HOLX) announced today that the Genius™ 3D Mammography™ exam is now the only mammogram that is FDA-approved as superior to standard 2D mammography for routine breast cancer screening of women with dense breasts.1 The Genius exam has been commercially available …
May, 2017
-
17 May
X-Chem and Vertex Enter Multi-Target Genetic Disease Partnership
WALTHAM, Mass.–(BUSINESS WIRE)–X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced a collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Under the terms of the agreement, X-Chem will apply its proprietary DEXTM libraries, which contain more than …
April, 2017
-
12 April
USPSTF Seeks Comments on Draft Recommendation Statement on Prostate Cancer Screening
WASHINGTON, April 11, 2017 /PRNewswire/ — The U.S. Preventive Services Task Force today posted for public comment a draft recommendation statement and three draft evidence reviews on screening for prostate cancer. Through this draft recommendation, the Task Force is providing clinicians and their patients with information to help guide decisions …